Hoth Therapeutics, Inc. (HOTH)
| Market Cap | 39.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.35M |
| Shares Out | 13.43M |
| EPS (ttm) | -0.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $2.47 |
| Previous Close | $2.32 |
| Change ($) | 0.15 |
| Change (%) | 6.47% |
| Day's Open | 2.35 |
| Day's Range | 2.33 - 2.50 |
| Day's Volume | 2,218,649 |
| 52-Week Range | 1.58 - 4.96 |
NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003...
NEW YORK, Jan. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced an agreement with Charles River Laboratories to initiate preclinica...
NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Non-Exclusive Commercial Evaluation Licen...
NEW YORK, Dec. 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed a production agreement for both GLP and GMP mate...
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the request for a Pre-Investigational New Drug (IND) meeting to the...
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearan...
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical dat...
NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced key upcoming milestones towards the commercial development of the no...
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that through its commercial licensing agreement with the University...
NEW YORK, Sept. 24, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced completing testing to examine the ability of HT-003 to block acne ...
NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement ("SRA") wi...
NEW YORK, Aug. 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc.
NEW YORK, Aug. 28, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc.
NEW YORK, Aug. 13, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc.
NEW YORK, July 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a licensing agreement with Isoprene Pharmaceuticals...
NEW YORK, June 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a sponsored research agreement with Virginia Commonwe...
NEW YORK, June 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member and inventor of novel peptide...
Wall Street sell-side analysts have issued buying recommendation ratings for shares of PDS Biotechnology Corp (NASDAQ:PDSB) and Hoth Therapeutics Inc (NASDAQ:HOTH), even though these stocks ha...
NEW YORK, June 8, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issue...
NEW YORK, May 27, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, announced today the closing of its previously announced un...
NEW YORK, May 22, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Michael H. Peters, Ph.D., has joined the company's Scientific A...
NEW YORK, May 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offe...
NEW YORK, May 20, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced licensing technology and intellectual property exclusively from Virg...
Technology Has Been Licensed from Massachusetts General Hospital Technology Has Been Licensed from Massachusetts General Hospital
Hoth (HOTH) soars following a joint venture with Voltron Therapeutics for a vaccine for COVID-19.
Hoth Therapeutics Inc (NASDAQ: HOTH) shares were roaring higher Monday after the biopharma announced its foray into COVID-19 vaccine development, joining a host of companies engaged in researc...
ORLANDO, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- It doesn’t take an analyst to suggest that high value merger and acquisition activity in any industry is a bullish sign. And it assuredly doe...
ORLANDO, Fla., Jan. 14, 2020 (GLOBE NEWSWIRE) -- The headline of our written offering today probably appears a little different from our regular titles. Typically we don’t lead with things t...
ORLANDO, Fla., Dec. 23, 2019 (GLOBE NEWSWIRE) -- As the holidays roll into November and December many companies go quietly into the New Year, eschewing news releases or large scale investor ...
About HOTH
Hoth Therapeutics, a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. It intends to use the BioLexa Platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company has license agreements with the George Washington University; the University of Maryland Baltimore; ... [Read more...]
| Industry Biotechnology | IPO Date Feb 15, 2019 |
| CEO Robb Knie | Employees 2 |
| Stock Exchange NASDAQ | Ticker Symbol HOTH |
Analyst Forecasts
According to one analyst, the rating for HOTH stock is "Strong Buy" and the 12-month stock price forecast is 10.00.